Study of Riamilovir Activity Against SARS-CoV-2 Infection In Syrian Hamsters
- 21 October 2021
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 66 (7-8), 13-19
- https://doi.org/10.37489/0235-2990-2021-66-7-8-13-19
Abstract
The activity of the antimetabolic drug Riamilovir (Triazavirin®) was studied on a model of SARS-CoV-2 infection on Syrian hamsters. Infectious process was caused by the intranasal administration of the virus accumulated in the Vero-B culture with a concentration of 4.25×104 TCID50, in a volume of 26 µl/hamster. The effects of the drug at a dose of 20 mg/kg intraperitoneally daily in the midst of the infectious process were traced to accelerate the clearance of the virus in the lungs, prevent body weight loss and the severity of pulmonary edema, as well as preserve the mass of the spleen. The protective effects of Riamilovir on the structure of the lungs and brain are shown, it is suggested that the drug has the ability to penetrate the blood-brain barrier. It was concluded that Riamilovir has antiviral activity against SARS-CoV-2.Keywords
This publication has 13 references indexed in Scilit:
- Triazavirin - Potential Inhibitor for 2019-nCoV Coronavirus M Protease: A DFT StudyCurrent Molecular Medicine, 2021
- Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 InfectionAntibiotics and Chemotherapy, 2021
- The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infectionTerapevticheskii arkhiv, 2020
- Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamstersNature Medicine, 2020
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelScience, 2020
- The Efficacy and Safety of Triazavirin for COVID-19: A Trial ProtocolEngineering, 2020
- Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drugInfekcionnye bolezni, 2019
- A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenzaInfekcionnye bolezni, 2017
- Computer modeling of blood brain barrier permeability of physiologically active compoundsBiomeditsinskaya Khimiya, 2014
- Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo-1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus ReplicationAntimicrobial Agents and Chemotherapy, 2010